Markets:

Overview

News

Currencies

International

Treasuries

GH Research PLC - Ordinary Shares (NQ:GHRS)

16.70 +0.36 (+2.20%)

Streaming Delayed Price Updated: 2:42 PM EDT, Apr 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GH Research PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Crude Oil Moves Higher; Owens & Minor Shares Plummet ↗

February 03, 2025

Via Benzinga

Dow Falls 150 Points; ISM Manufacturing PMI Rises In January ↗

February 03, 2025

Via Benzinga

Topics Stocks

IDEXX Laboratories Posts Upbeat Results, Joins Stratasys, Saia And Other Big Stocks Moving Higher On Monday ↗

February 03, 2025

Via Benzinga

Why Is GH Research Stock Trading Higher On Monday? ↗

February 03, 2025

GH Research's Phase 2b trial of GH001 for treatment-resistant depression met its primary endpoint, showing significant efficacy and a favorable safety profile.

Via Benzinga

S&P 500 Down Over 1%; Tyson Foods Posts Upbeat Results ↗

February 03, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 03, 2025

Via Benzinga

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

February 03, 2025

From GH Research PLC

Via GlobeNewswire

Why Triumph Group Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket ↗

February 03, 2025

Via Benzinga

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

January 31, 2025

From GH Research PLC

Via GlobeNewswire

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 22, 2025

Via Benzinga

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

January 10, 2025

From GH Research PLC

Via GlobeNewswire

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

November 14, 2024

From GH Research PLC

Via GlobeNewswire

3 Fast-Growing Stocks Analysts See Doubling in Price

November 11, 2024

Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.

Via MarketBeat

Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week ↗

September 15, 2024

The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.

Via Talk Markets

Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th ↗

September 10, 2024

While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are...

Via Talk Markets

Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August ↗

September 06, 2024

The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a...

Via Talk Markets

Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials ↗

September 05, 2024

Irish psychedelic biotech firm GH Research PLC (NASDAQ: GHRS) reported on Tuesday financial results for the second quarter ended June 30, 2024. Cash, cash equivalents, other financial assets and...

Via Benzinga

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

September 03, 2024

From GH Research PLC

Via GlobeNewswire

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer

September 03, 2024

From GH Research PLC

Via GlobeNewswire

Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week ↗

August 24, 2024

Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past...

Via Talk Markets

Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD ↗

August 15, 2024

This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest...

Via Talk Markets

Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗

July 14, 2024

The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...

Via Talk Markets

3 Psychedelic Stocks to Ride to the Moon and Beyond ↗

July 06, 2024

Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market.

Via InvestorPlace

Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns ↗

July 03, 2024

Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks.

Via InvestorPlace

Largest Clinical-Stage BioTech Drug Stocks Declined 6% ↗

June 22, 2024

Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...

Via Talk Markets

Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why ↗

June 09, 2024

Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA.

Via Talk Markets

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

June 05, 2024

Via Benzinga

Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week ↗

May 27, 2024

This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our...

Via Talk Markets

Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week ↗

May 13, 2024

Via Talk Markets

Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May ↗

May 05, 2024

We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.